Atox Bio Ltd.
- Country
- 🇮🇱Israel
- Ownership
- Private
- Established
- 2003-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.atoxbio.com
Clinical Trials
5
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury
- Conditions
- Necrotizing Soft Tissue InfectionPeritonitisAcute Kidney Injury
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-01-19
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Atox Bio Ltd
- Target Recruit Count
- 58
- Registration Number
- NCT03403751
- Locations
- 🇺🇸
Maricopa Medical Center, Phoenix, Arizona, United States
🇺🇸Banner University Medical Center, Tucson, Arizona, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections
- Conditions
- Fournier's GangreneNecrotizing FasciitisNecrotizing Soft Tissue Infections
- Interventions
- Drug: AB103 0.5 mg/kgOther: NaCl 0.9%
- First Posted Date
- 2015-06-12
- Last Posted Date
- 2021-10-05
- Lead Sponsor
- Atox Bio Ltd
- Target Recruit Count
- 290
- Registration Number
- NCT02469857
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Maricopa Medical Center, Phoenix, Arizona, United States
🇺🇸Banner University Medical Center, Tucson, Arizona, United States
Evaluation of Safety, PK and Immunomodulatory Effects of AB103 in Necrotizing Soft Tissue Infections Patients
- First Posted Date
- 2011-08-16
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- Atox Bio Ltd
- Target Recruit Count
- 43
- Registration Number
- NCT01417780
- Locations
- 🇺🇸
University of Southern California Los Angeles, Los Angeles, California, United States
🇺🇸San Francisco General Hospital, San Francisco, California, United States
🇺🇸University of Florida, Gainesville, Florida, United States
AB103 Peptide Antagonist in Healthy Volunteers
- First Posted Date
- 2010-07-21
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- Atox Bio Ltd
- Target Recruit Count
- 25
- Registration Number
- NCT01166984
- Locations
- 🇺🇸
University of Maryland School of Medicine, Baltimore, Maryland, United States